Lancet study finds no benefit for hydroxychloroquine in COVID-19 patients

The scientists said these drugs should not be used to treat COVID-19 patients outside of clinical trials until results from randomised clinical trials are available to confirm their safety and efficacy for COVID-19 patients. They explained chloroquine, an antimalarial drug and its analogue, hydroxychloroquine, are commonly used to treat autoimmune diseases.
Source: The Economic Times - Category: Consumer Health News Source Type: news

Related Links:

Acute disseminated encephalomyelitis (ADEM) is a rare autoimmune disease of the CNS that often after viral infections and mainly affecting children. ADEM is characterized by the onset of multifocal neurologic symptoms, encephalopathy, with brain MRI showing demyelinating abnormalities in the acute phase.1 Coronavirus disease 2019 (COVID-19) is a novel entity caused by the pandemic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is characterized by influenza-like symptoms, pneumonia, and in severe cases respiratory insufficiency.2 Many neurologic complications occurring in patients with COVID-19 have bee...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: COVID-19, Acute disseminated encephalomyelitis Clinical/Scientific Notes Source Type: research
Patients who rely on chloroquine and other medications fear they won ’t be able to get needed refills because of high demand.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Hydroxychloroquine (Drug) Pain-Relieving Drugs Shortages Stockpiling Antibiotics Autoimmune Diseases Infections Joints (Body Part) Source Type: news
(GENEVA) — The World Health Organization said Monday that it will temporarily drop hydroxychloroquine — the anti-malarial drug U.S. President Trump says he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date. In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be “a temporary pause” on the hydroxychloroquine arm of its g...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 News Desk overnight wire Source Type: news
Abstract The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease,...
Source: Accident and Emergency Nursing - Category: Emergency Medicine Authors: Tags: Arch Acad Emerg Med Source Type: research
AbstractA pandemic due to novel coronavirus arose in mid-December 2019 in Wuhan, China, and in 3  months’ time swept the world. The disease has been referred to as COVID-19, and the causative agent has been labelled SARS-CoV-2 due to its genetic similarities to the virus (SARS-CoV-1) responsible for the severe acute respiratory syndrome (SARS) epidemic nearly 20 years earlier. The spike pro teins of both viruses dictate tissue tropism using the angiotensin-converting enzyme type 2 (ACE-2) receptor to bind to cells. The ACE-2 receptor can be found in nervous system tissue and endothelial cells among the tiss...
Source: Journal of NeuroVirology - Category: Neurology Source Type: research
ConclusionsThis is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
In the largest observational study thus far investigating the drug hydroxychloroquine as a treatment for COVID-19, researchers found little evidence that it helps, and worrying evidence that the medication may cause harm. In a study published May 22 in the journal Lancet, scientists in the U.S. and Switzerland report on an analysis of more than 96,000 people hospitalized with confirmed COVID-19 in 671 hospitals on six continents. Nearly 15,000 patients were treated with one of the following: chloroquine (which is an older version of hydroxychloroquine), hydroxychloroquine, or either of those drugs in combination with an an...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
By HANS DUVEFELT, MD From the vantage point of our self-quarantined shrunken universes, we cannot see even the immediate future, let alone what our personal and professional lives will look like some years from now. Factories are closed, luxury department stores are in bankruptcy, hospitals have stopped performing elective procedures and patients are having their heart attacks at home, unattended by medical professionals. New York office workers may continue to work from home while skyscrapers stand empty and city tax revenues evaporate. Quarantined and furloughed families are planting gardens and cooking at h...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: COVID-19 Medical Practice Hans Duvefelt Source Type: blogs
Conditions:   COVID-19;   Systemic Lupus Erythematosus;   Sjogren's Syndrome;   Axial Spondyloarthritis;   Rheumatoid Arthritis;   Giant Cell Arteritis Intervention:   Sponsors:   Pitié-Salpêtrière Hospital;   Groupe d'Études et de Recherche de l'Appareil Locomoteur (GERPAL);   Università degli Studi di Ferrara;   Rheumazentrum Ruhrgebiet;   University College, London;   University of Coimbra;   Universidad Complutense de ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   COVID-19;   Systemic Lupus Erythematosus;   Sjogren's Syndrome;   Axial Spondyloarthritis;   Rheumatoid Arthritis;   Giant Cell Arteritis Intervention:   Sponsors:   Pitié-Salpêtrière Hospital;   Groupe d'Études et de Recherche de l'Appareil Locomoteur (GERPAL);   Università degli Studi di Ferrara;   Rheumazentrum Ruhrgebiet;   University College, London;   University of Coimbra;   Universidad Complutense de ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Autoimmune Disease | Clinical Trials | COVID-19 | Health | Hydroxychloroquine | Study